Concept visual: Wild Bite Club.
Native grain fractions are testing whether protein and prebiotic fibre can deliver stronger nutrition without the usual taste, texture or tolerance penalty.
What Is Changing
Grain processors are beginning to treat fractions left around starch and ethanol production as formulation assets rather than low-value co-products. The emerging proposition combines two different tools: concentrated barley protein for structure and nutrition, and native corn arabinoxylan for fibre enrichment at comparatively low inclusion rates. ClonBio Foods currently presents PurusPro barley protein and FibAX corn arabinoxylan, while Pannonia Bio lists barley protein and soluble corn fibre from its integrated biorefinery. That pairing matters because it turns a bulk-processing system into an ingredient platform. Instead of building a plant around a single finished product, an operator can separate starch, protein and fibre streams and direct each towards a different finished-food use. The commercial question is whether those fractions can perform cleanly and consistently enough to earn ingredient margins rather than commodity returns.
Where It Could Go
If the economics hold, the platform could travel across bakery, cereal, bars, extruded snacks, beverages and specialised nutrition. Barley protein could support a cereal-forward alternative to pea or soy in products where its flavour and colour are an asset rather than a defect. Native corn fibre could be used alone for fortification or paired with protein to build a more complete grain-derived proposition. One plausible route is a bakery system in which fibre replaces part of the bulking function lost when sugar is reduced, while protein supports structure and nutritional positioning. Another is a snack or breakfast format that uses both fractions but still communicates familiar grain origins. These are scenarios, not announced products. Adoption would depend on supply reliability, allergen and gluten management, regional regulatory treatment, tolerance at the intended serving, and whether the combined ingredient cost is offset by simpler recipes or stronger consumer value.
How It Works
The protein and fibre routes begin with grain but separate its components in different ways. A barley-protein process described in WIPO publication WO2021183238 mills the grain, creates an aqueous slurry, uses enzymes to solubilise starch, separates a protein-rich fraction and dries it into a concentrate. The claims describe a product with more than 54% barley protein and include recovery and reuse of process water. Fermentation is not required for that protein-recovery step. The arabinoxylan route targets the branched polysaccharide embedded in corn cell walls. ClonBio says FibAX is isolated while preserving its native length and branched structure; trade reporting describes the ingredient as distinct from shorter, heavily broken-down fibre fragments. In practical formulation terms, protein concentration changes the nutritional and structural contribution of the grain, while intact arabinoxylan changes how much fibre can be added, how it disperses and where it is fermented in the gut. Those outcomes still depend on purity, particle size, hydration and the finished-food matrix.
Why It Matters
Protein enrichment and fibre fortification often solve one nutritional brief while creating a sensory or digestive problem. Grain proteins can bring colour, cereal flavour, grittiness or weak solubility. Some isolated fibres require relatively high use levels, thicken unexpectedly or ferment rapidly enough to limit comfortable serving sizes. A native, highly branched arabinoxylan offers a different formulation hypothesis: preserve more of the corn cell-wall structure, then use a smaller amount to add fibre while protecting taste and texture. An independent report on FibAX describes slow, sustained fermentation and cites a cake trial using 1.5% of the ingredient alongside reduced sugar. That is promising formulation evidence, not proof that every application will behave the same way. For consultants, the transferable question is whether a low-dose fibre can create room for sugar reduction, protein enrichment or texture management without making the product feel conspicuously reformulated.
What to Watch
The most useful next signal is production, not another concept claim. ClonBio has announced a commercial-scale FibAX facility at Dunaföldvár that an independent trade report says is expected to operate in the second quarter of 2027; the ingredient is currently described as pilot-scale. Consultants should watch for validated capacity, customer sampling, application data outside cake, and finished products that disclose meaningful fibre levels. Independent sensory work would be especially valuable in beverages and light-coloured bakery, where grain notes and turbidity are difficult to hide. Human tolerance and microbiome studies should test realistic portions rather than purified laboratory doses. On the protein side, useful evidence would include solubility curves, amino-acid quality, heat stability and performance against pea, soy and wheat benchmarks. Finally, the market needs transparent pricing and co-product accounting to show whether circularity improves the business case rather than merely the narrative.
The WBC Read
This is a credible ingredient-platform development because the mechanism and the manufacturing pathway are visible: grain is being fractionated into higher-value protein and native fibre rather than sold only as starch, feed or fuel co-products. The strongest evidence comes from an operating biorefinery, named ingredients, a detailed production process and a disclosed scale-up plan. The uncertainties are equally material. Pilot behaviour may not survive full-scale separation and drying, a low use level in one bakery test does not establish broad digestive or sensory performance, and barley protein will still face application-specific colour, flavour and gluten constraints. The development deserves close attention, particularly for reformulation briefs where protein, fibre and sugar reduction collide. It should be treated as a practical formulation hypothesis with growing operational support, not as a universal replacement for established proteins or fibres.